ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Lin Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7376-4082; OpenAlex author ID A5101449398. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 13

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 2 papers

Papers 3

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.22.02630 ↗
Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. Last author DOI 10.3389/fonc.2023.1151178 ↗
ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. Last author DOI 10.3389/fonc.2021.724815 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kai Ou · 2 shared papers, 2021–2023 · strength 0.38
- Paper Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case r… DOI 10.3389/fonc.2023.1151178 ↗
- Paper ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Re… DOI 10.3389/fonc.2021.724815 ↗
Xiaoting Ma · 1 shared paper, 2023 · strength 0.22
- Paper Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case r… DOI 10.3389/fonc.2023.1151178 ↗
Chunyi Hao · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Ying Yuan · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Hongmei Zhang · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Lin Shen · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Jianming Xu · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Rui‐Hua Xu · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Qingshan Zheng · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Jin Li · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Jun Zhang · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Shukui Qin · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗
Deliang Fu · 1 shared paper, 2023 · strength 0.13
- Paper Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. DOI 10.1200/jco.22.02630 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.